Biologics for treatment of juvenile idiopathic arthritis - Update 2007;Biologika zur therapie der juvenilen idiopathischen arthritis - Update 2007

Aktuelle Rheumatologie

Volumn 32, Issue 3, 2007, Pages 128-135

  Horneff, Gerd ^a  

^a Asklepios Klinik Sankt Augustin   (Germany)

Author keywords

Abatacept; Adalimumab; Anakinra; Etanercept; Infliximab; Juvenile idiopathic arthritis; Rilonacept; Tocilizumab; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CYTOKINE PRODUCTION; DEPRESSION; DRUG EFFICACY; FATIGUE; HUMAN; INFLAMMATION; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; MORNING STIFFNESS; UVEITIS;

EID: 34447636961     PISSN: 0341051X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963238     Document Type: Article

References (31)

1. Armbrust W, Kamphuis SS, Wolfs TW et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004; 43: 527-529
2. Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol 2002; 29: 1111-1114
3. Biester S, Deuter C, Michels H et al. Adalimumab in the Therapy of Uveitis in Childhood. Br J Ophthalmol 2006; 11: Epub ahead of print
4. Fantini nnn et al. Infliximab in the treatment of refractory JIA Pres Meeting Abstract. Ann Rheum Dis 2000; 9: 7418
5. Giannini EH, Ruperto N, Raveli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-1209
6. Giannini EH, Ruperto N, Prieur AM et al. Efficacy and Safety of Abatacept in Children and Adolescents with Active Juvenile Idiopathic Arthritis (JIA): Results of Double-Blind Withdrawal Phase. Arthritis Rheum 2006; 54: Abs 482
7. Haibel H, Rudwaleit M, Brandt HC et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006; 54: 678-681
8. Horneff G, Schmeling H, Biedermann T et al. The German Etanercept Registry for Treatment of Juvenile Idiopathic Arthritis (JIA). Ann Rheum Dis 2004; 63: 1638-1644
9. Horneff G, Ruperto N, Martini A et al. Behandlung von Kindern mit juveniler rheumatoider Arthritis (JRA) mit Adalimumab - Studienergebnisse nach 48 Wochen. Z Rheumatol 2006; 65: S6
10. Ilowite NT, Porras O, Reiff A et al. A twelve-week open label safety and efficacy study of anakinra (Kineret) in juvenile rheumatoid arthritis. Ann Rheum Dis 2003; 62: 87S
11. Ilowite N, Reiff A, Rudge S et al. A randomized, multi-center, blinded, placebo-controlled study with an open-label run-in period to evaluate Anakinra in polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54 (Suppl): S327
12. Imagawa T, Mori M, Takei S et al. Efficacy and Safety of tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in Patients with Polyarticular or Oligoarticular Onset Juvenile Idiopathic Arthritis. Arthritis Rheum 2006; 54: S327
13. Irigoyen P, Olson J, Hom C et al. Treatment of systemic onset juvenile idiopathic arthritis with Anakinra. Pedrheumonline 2006; 3: 123-134
14. Kahn P, Weiss M, Imundo LF et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 5: 864, e1-Epub 2006
15. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411
16. Kimura Y, Imundo LF, Li SC. High dose infliximab in the treatment of resistant systemic JRA. Arthritis Rheum 2001; 44: 272S
17. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62: 245-247
18. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-769
19. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54: 1987-1994
20. Lovell DJ, Ruperto N, Cuttica R et al. Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg Infliximab plus Methotrexate therapy in JRA patients. Arthritis Rheum 2005; 52: 724S
21. Lovell DJ, Giannini EH, Kimura Y et al. Preliminary Evidence for Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-1 Inhibitor, In Systemic Juvenile Idiopathic Arthritis (SJIA). Arthritis Rheum 2006; 54: S325
22. Lovell DJ, Ruperto N, Jung L et al. Long-Term Efficacy and Safety of Adalimumab in Children with Juvenile Rheumatoid Arthritis (JRA): 48-Week Results. Arthritis Rheum 2006; 54: S326
23. Lovell DJ, Ruperto N, Prieur AM et al. Assessment of open label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis. Arthritis Rheum 2006; 54 (Suppl): S326
24. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-3289
25. Perry RE, Southwood TR, Baum J et al. Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991-1994
26. Ruperto N, Lovell DJ, Goodman S et al. 48 week data from the study of Adalimumab in Children with Juvenile Rheumatoid Arthritis (JRA). EULAR Amsterdam 21. - 24.6.06. Ann Rheum Dis 2006; 65 (Suppl 1): 56
27. Smith JA, Thompson DJS, Whitcup SM et al. A randomised, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23
28. Tutar E, Ekici F, Nacar N et al. Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2004; 43: 674-675
29. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 4: 572-575
30. Woo P, Wilkinson N, Prieur AM et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: 1281-1288
31. Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-825